Arii S - Search Results

1

TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.

Yasui K, Arii S, Zhao C, Imoto I, Ueda M, Nagai H, Emi M, Inazawa J. Yasui K, et al. Among authors: arii s. Hepatology. 2002 Jun;35(6):1476-84. doi: 10.1053/jhep.2002.33683. Hepatology. 2002. PMID: 12029633

2

PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas.

Okamoto H, Yasui K, Zhao C, Arii S, Inazawa J. Okamoto H, et al. Among authors: arii s. Hepatology. 2003 Nov;38(5):1242-9. doi: 10.1053/jhep.2003.50457. Hepatology. 2003. PMID: 14578863

3

Association of over-expressed TFDP1 with progression of hepatocellular carcinomas.

Yasui K, Okamoto H, Arii S, Inazawa J. Yasui K, et al. Among authors: arii s. J Hum Genet. 2003;48(12):609-613. doi: 10.1007/s10038-003-0086-3. Epub 2003 Nov 15. J Hum Genet. 2003. PMID: 14618416

4

Activation of B-Myb by E2F1 in hepatocellular carcinoma.

Nakajima T, Yasui K, Zen K, Inagaki Y, Fujii H, Minami M, Tanaka S, Taniwaki M, Itoh Y, Arii S, Inazawa J, Okanoue T. Nakajima T, et al. Among authors: arii s. Hepatol Res. 2008 Sep;38(9):886-95. doi: 10.1111/j.1872-034X.2008.00324.x. Hepatol Res. 2008. PMID: 18624722

5

miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma.

Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. Furuta M, et al. Among authors: arii s. Carcinogenesis. 2010 May;31(5):766-76. doi: 10.1093/carcin/bgp250. Epub 2009 Oct 20. Carcinogenesis. 2010. PMID: 19843643

6

Integrative array-based approach identifies MZB1 as a frequently methylated putative tumor suppressor in hepatocellular carcinoma.

Matsumura S, Imoto I, Kozaki K, Matsui T, Muramatsu T, Furuta M, Tanaka S, Sakamoto M, Arii S, Inazawa J. Matsumura S, et al. Among authors: arii s. Clin Cancer Res. 2012 Jul 1;18(13):3541-51. doi: 10.1158/1078-0432.CCR-11-1007. Epub 2012 May 9. Clin Cancer Res. 2012. PMID: 22573353

7

FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.

Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, Hagiwara S, Sakurai T, Haji S, Kanazawa A, Hidaka H, Iso Y, Kubota K, Shimada M, Utsunomiya T, Hirooka M, Hiasa Y, Toyoki Y, Hakamada K, Yasui K, Kumada T, Toyoda H, Sato S, Hisai H, Kuzuya T, Tsuchiya K, Izumi N, Arii S, Nishio K, Kudo M. Arao T, et al. Among authors: arii s. Hepatology. 2013 Apr;57(4):1407-15. doi: 10.1002/hep.25956. Epub 2013 Feb 11. Hepatology. 2013. PMID: 22890726

8

The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma.

Furuta M, Kozaki K, Tanimoto K, Tanaka S, Arii S, Shimamura T, Niida A, Miyano S, Inazawa J. Furuta M, et al. Among authors: arii s. PLoS One. 2013;8(3):e60155. doi: 10.1371/journal.pone.0060155. Epub 2013 Mar 27. PLoS One. 2013. PMID: 23544130 Free PMC article.

9

Skp2 overexpression is a p27Kip1-independent predictor of poor prognosis in patients with biliary tract cancers.

Sanada T, Yokoi S, Arii S, Yasui K, Imoto I, Inazawa J. Sanada T, et al. Among authors: arii s. Cancer Sci. 2004 Dec;95(12):969-76. doi: 10.1111/j.1349-7006.2004.tb03185.x. Cancer Sci. 2004. PMID: 15596046 Free PMC article.

10

Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy.

Tanaka S, Arii S, Yasen M, Mogushi K, Su NT, Zhao C, Imoto I, Eishi Y, Inazawa J, Miki Y, Tanaka H. Tanaka S, et al. Among authors: arii s. Br J Surg. 2008 May;95(5):611-9. doi: 10.1002/bjs.6011. Br J Surg. 2008. PMID: 18311747 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

334 results

Search Page

Filters